Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview.
about
Fundamental aspects of solid dispersion technology for poorly soluble drugsPyrazolopyridine Inhibitors of B-Raf V600E . Part 1: The Development of Selective, Orally Bioavailable, and Efficacious InhibitorsModulating Drug Release and Enhancing the Oral Bioavailability of Torcetrapib with Solid Lipid Dispersion Formulations.Insights into atomic-level interaction between mefenamic acid and eudragit EPO in a supersaturated solution by high-resolution magic-angle spinning NMR spectroscopy.Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.In vitro and in vivo evaluation of amorphous solid dispersions generated by different bench-scale processes, using griseofulvin as a model compound.Physicochemical properties and mechanisms of drug release from melt-extruded granules consisting of chlorpheniramine maleate and Eudragit FS.Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma.Solid-state characterization of Felodipine-Soluplus amorphous solid dispersions.Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility.Overview of drug product development.Hot-melt extrusion--basic principles and pharmaceutical applications.Amorphous solid dispersions: a robust platform to address bioavailability challenges.Melt-Extruded Eudragit® FS-Based Granules for Colonic Drug Delivery.Use of Polyvinyl Alcohol as a Solubility-Enhancing Polymer for Poorly Water Soluble Drug Delivery (Part 1).Crosslinked hydrogels-a promising class of insoluble solid molecular dispersion carriers for enhancing the delivery of poorly soluble drugs.Evaluation of the Microcentrifuge Dissolution Method as a Tool for Spray-Dried Dispersion.The role of the carrier in the formulation of pharmaceutical solid dispersions. Part II: amorphous carriers.Bioavailability enhancement of a BCS IV compound via an amorphous combination product containing ritonavir.A Model-Based Methodology for Spray-Drying Process Development.Eudragit L/HPMCAS blend enteric-coated lansoprazole pellets: enhanced drug stability and oral bioavailability.Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug.In vitro characterization of a novel polymeric system for preparation of amorphous solid drug dispersionsDesign and Solidification of Fast-Releasing Clofazimine Nanoparticles for Treatment of Cryptosporidiosis.Incorporation of physiologically based pharmacokinetic modeling in the evaluation of solubility requirements for the salt selection process: a case study using phenytoin.Evaluation of drug load and polymer by using a 96-well plate vacuum dry system for amorphous solid dispersion drug delivery.Dissolution enhancement of a drug exhibiting thermal and acidic decomposition characteristics by fusion processing: a comparative study of hot melt extrusion and KinetiSol dispersing.Initial Drug Dissolution from Amorphous Solid Dispersions Controlled by Polymer Dissolution and Drug-Polymer Interaction.Evaluation of Influence of Various Polymers on Dissolution and Phase Behavior of Carbamazepine-Succinic Acid Cocrystal in Matrix Tablets.Atmospheric freeze drying for the reduction of powder electrostatics of amorphous, low density, high surface area pharmaceutical powders.Stabilization of fenofibrate in low molecular weight hydroxypropylcellulose matrices produced by hot-melt extrusion.Formulating weakly basic HCl salts: relative ability of common excipients to induce disproportionation and the unique deleterious effects of magnesium stearate.Design of experiments utilization to map the processing capabilities of a micro-spray dryer: particle design and throughput optimization in support of drug discovery.A solid-state NMR study of amorphous ezetimibe dispersions in mesoporous silica.Using Environment-Sensitive Fluorescent Probes to Characterize Liquid-Liquid Phase Separation in Supersaturated Solutions of Poorly Water Soluble Compounds.Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection.Impact of Drug-Polymer Miscibility on Enthalpy Relaxation of Irbesartan Amorphous Solid Dispersions.Characterization and pharmacokinetic study of itraconazole solid dispersions prepared by solvent-controlled precipitation and spray-dry methods.A framework for multi-scale simulation of crystal growth in the presence of polymers.Probing the effects of experimental conditions on the character of drug-polymer phase diagrams constructed using Flory-Huggins theory.
P2860
Q26822873-FDD77DC5-F678-4408-8F63-4949F64781A5Q27684109-91FA005C-BBC3-4A58-AA52-38998C425E47Q30390764-B143E510-692F-4D99-A85E-2A54AD8CCEA6Q30702880-4ADE5C81-7786-48DD-B7B7-B9EBB699C01FQ33599811-9921477A-57C4-4ABD-8CAE-1A51F0A3E01BQ34605997-15D5BF1C-744D-4D2D-8C4C-E130C3C110F1Q35660917-099EFBEE-8791-4ECA-A970-9A57DB23F39EQ36641553-05A04563-3705-4703-B7B3-F054223BBFABQ37066636-A8FDA6FC-9648-4513-A8D4-18CF1AF5E9F0Q37802897-1BFDEB31-F17D-401F-9221-F7B587572260Q37965423-C0D4AC53-50E0-4D27-95D3-67189C3B1410Q38187427-14CFCD5D-6608-4D1B-AFF7-510F5CE6E682Q38358879-4D502588-DFEB-4F6A-A520-E6246B47000CQ38619418-F2DD82B8-72B0-4E01-9316-37D9312DCB42Q38619585-0C5F0F11-B53D-4374-AFEF-3AD1A98EACCAQ38636974-DC408061-1F26-41DE-BE49-23A91C6922ABQ38790553-617B8023-B204-48F1-9360-2514F81E29CCQ38856754-DF610922-8146-4052-99F5-80C483E71933Q38954732-DA6E91A5-4AEB-4683-86B2-5756DC9D9200Q39578961-B03978C6-01E2-43F0-B4B7-C87A9B148088Q40027295-2D391A20-5F23-4912-85FA-F84FDB8220C8Q40620607-0C9F68A6-F1D4-4317-B739-5CE52A154AD1Q41150354-E190F3DD-A1A8-4AA4-861D-318BFEF17434Q41769211-EB36DB9E-0AED-4E8F-A641-7D5AD9649133Q41820686-513BCA95-2796-4256-9874-3A62AD1F22DAQ41988287-3B57B4CA-0604-4F1A-9177-B26919C2F93FQ41988865-CDCCCC42-62F1-4B61-AB34-037958FB0542Q42104195-0C1068A6-914A-478D-A265-4612FEE7D615Q42581894-0D063A24-26EF-4029-8B8C-3D1BE7EAF12CQ43601553-5C588F09-3FB4-47EC-922C-8A094668A817Q43854886-FFBF5668-E06D-4981-88FF-9C7D6717FEC1Q44767781-31B966A5-E542-4C3A-B72A-DEE810999B54Q45092890-8C9D8393-FA77-48AA-BD9C-57FE12603BF8Q45164709-08797F5E-075C-4250-8597-157AB3097438Q46049295-52676935-CE0F-45C3-A7CD-0D74E20EEA61Q46688318-2F5A28FA-B715-41FE-83D7-5F065449F50BQ47646957-ABAC3251-BBF5-402D-80DF-47B29CF7F130Q47900371-3B32157C-1853-48FF-95F3-02E9FF97F677Q48047695-4458E5B7-7581-4AC1-ABBC-9190872078DFQ48244592-6277928B-5D12-408E-BA80-567996B5ABD5
P2860
Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Hydroxypropyl methylcellulose ...... ried dispersions: an overview.
@en
Hydroxypropyl methylcellulose ...... ried dispersions: an overview.
@nl
type
label
Hydroxypropyl methylcellulose ...... ried dispersions: an overview.
@en
Hydroxypropyl methylcellulose ...... ried dispersions: an overview.
@nl
prefLabel
Hydroxypropyl methylcellulose ...... ried dispersions: an overview.
@en
Hydroxypropyl methylcellulose ...... ried dispersions: an overview.
@nl
P2093
P356
P1476
Hydroxypropyl methylcellulose ...... ried dispersions: an overview.
@en
P2093
Daniel T Smithey
Dwayne T Friesen
J A S Nightingale
Marshall Crew
Ravi Shanker
W J Curatolo
P304
P356
10.1021/MP8000793
P407
P577
2008-11-01T00:00:00Z